Myomo, Inc., a commercial stage medical robotics company, designs, develops, and produces myoelectric braces or orthotics for people suffering with neuromuscular disorders in the United States. It offers MyoPro, a powered upper limb orthosis that supports the arm, as well as restores function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, ALS, or other neuromuscular disease or injury. The company serves orthotics and prosthetics practices or clinics, as well as the veteran administration and other hospitals through orthotics and prosthetics providers, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Medical Devices
Sub-IndustryN/A
SectorMedical
Phone+1-617-9969058
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees22
OptionableNot Optionable
Myomo (NYSEAMERICAN:MYO) Frequently Asked Questions
What is Myomo's stock symbol?
Myomo trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MYO."
How were Myomo's earnings last quarter?
Myomo Inc (NYSEAMERICAN:MYO) issued its quarterly earnings data on Monday, November, 5th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by $0.01. The company had revenue of $0.61 million for the quarter, compared to analyst estimates of $0.82 million. View Myomo's Earnings History.
When is Myomo's next earnings date?
What price target have analysts set for MYO?
2 equities research analysts have issued twelve-month price targets for Myomo's stock. Their predictions range from $7.00 to $12.00. On average, they anticipate Myomo's stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 446.0% from the stock's current price. View Analyst Price Targets for Myomo.
What is the consensus analysts' recommendation for Myomo?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myomo in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Myomo.
Has Myomo been receiving favorable news coverage?
News stories about MYO stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Myomo earned a news sentiment score of 0.9 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the company's share price in the next several days.
Are investors shorting Myomo?
Myomo saw a decrease in short interest during the month of December. As of December 31st, there was short interest totalling 659,684 shares, a decrease of 18.2% from the December 14th total of 806,700 shares. Based on an average daily trading volume, of 102,310 shares, the days-to-cover ratio is presently 6.4 days. Currently, 6.4% of the shares of the company are sold short. View Myomo's Current Options Chain.
Who are some of Myomo's key competitors?
Some companies that are related to Myomo include Activecare (ACAR), Advanced Oncotherapy (AVO), Airware Labs (AIRW), Anteo Diagnostics (ADO), Aurora Spine (ASG), Avacta Group (AVCT), Azure Healthcare (AZV), Cannabix Technologies (BLOZF), Cochlear (COH), ConvaTec Group (CTEC), Creo Medical Group (CREO), Draegerwerk AG & Co KGaA (DRW3), Electromed (ELMD), Ellex Medical Lasers (ELXMF) and EMvision Medical Devices (EMV).
Who are Myomo's key executives?
Myomo's management team includes the folowing people:
- Mr. Paul R. Gudonis, Chairman, Pres & CEO (Age 63)
- Ms. Davie Mendelsohn RN, VP of Sales & Clinical Services (Age 64)
- Mr. Jonathan Naft, VP & GM (Age 53)
- Mr. Ralph A. Goldwasser, Chief Financial Officer (Age 70)
- Mr. Clifford J. Conneighton, Chief Marketing Officer (Age 68)
How do I buy shares of Myomo?
Shares of MYO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Myomo's stock price today?
One share of MYO stock can currently be purchased for approximately $1.74.
What is Myomo's official website?
How can I contact Myomo?
Myomo's mailing address is One Broadway, 14Th Floor, CAMBRIDGE, MA 02142, United States. The company can be reached via phone at +1-617-9969058.
MarketBeat Community Rating for Myomo (NYSEAMERICAN MYO)
MarketBeat's community ratings are surveys of what our community members think about Myomo and other stocks. Vote "Outperform" if you believe MYO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYO will underperform the S&P 500 over the long term. You may vote once every thirty days.
